# A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

> **NCT05927571** · PHASE1 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Cevostamab
- **DRUG:** Elranatamab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05927571
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05927571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05927571, "A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05927571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*